HM
NKGN

Howard Marks’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Howard Marks’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$1.01M – 261
2023
Q1 		$1.01M Hold
100,000
– – 0.01% 279
2022
Q4 		$995K Hold
100,000
– – 0.01% 318
2022
Q3 		$975K Hold
100,000
– – 0.01% 348
2022
Q2 		$971K Hold
100,000
– – 0.01% 335
2022
Q1 		$970K Hold
100,000
– – 0.01% 323
2021
Q4 		$967K Sell
100,000
-50,000
-33% -$486K 0.01% 316
2021
Q3 		$1.45M Buy
+150,000
New +$1.46M 0.02% 231

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return

Howard Marks's NKGN Position: Q2 2023 in Review

Howard Marks sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 100,000 shares — an estimated $1.01M sold.

Howard Marks first reported a position in NKGN in Q3 2021 and held it in 7 quarters. The position peaked at $1.45M in Q3 2021. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • Howard Marks reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Howard Marks sold 100,000 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $1.01M.
  • Howard Marks first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
  • Howard Marks's NKGen Biotech, Inc. Common Stock position peaked at $1.45M in Q3 2021.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on Oaktree Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.